• Investors may be wondering whether Liquidia at around US$37.34 is still offering value after a strong run, or if most of the opportunity is already reflected in the price.
• The stock shows a 0.8% decline over the last 7 days, a 6.6% gain over 30 days, an 18.9% return year to date, a 162.4% return over 1 year, and a very large 3 year and 5 year performance that may catch your eye when judging risk and reward.
• Recent coverage has focused on Liquidia's share price performance and how the market is reacting to company specific developments. Investors are paying close attention to how these factors shape expectations for the business. This context is important because it can influence whether current valuation multiples appear stretched, reasonable, or conservative relative to those expectations.
• Simply Wall St currently assigns Liquidia a valuation score of 2 out of 6, so next up is a closer look at the standard valuation checks, followed by a way of thinking about valuation that goes beyond any single model.

Liquidia scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Liquidia Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and then discounting those back to a present value. It essentially asks what those future dollars are worth in today's terms.

For Liquidia, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections in $. The latest twelve month free cash flow is a loss of $57.4 million, so the focus is on what the business might generate in the future rather than what it is producing today.

Analysts and extrapolated estimates feed into ten year projections, with free cash flow in 2030 projected at $858.7 million and a series of annual estimates leading up to that point. Simply Wall St then discounts each of those projected cash flows back to today, which results in an estimated intrinsic value of about $248.84 per share.

Compared with a recent share price around $37.34, this DCF output suggests the stock is 85.0% undervalued based on those assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Liquidia is undervalued by 85.0%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Approach 2: Liquidia Price vs Sales

Price to sales, or P/S, is often a useful yardstick for companies that are not yet profitable, because it compares what investors are paying to the revenue being generated rather than to earnings that may still be negative.

In general, higher expected growth and lower perceived risk can justify a higher P/S ratio, while slower growth or higher uncertainty usually point to a lower, more conservative multiple as being more typical.

Liquidia currently trades on a P/S ratio of 20.78x. This sits well above the Pharmaceuticals industry average of 4.37x and the peer average of 7.33x. This suggests the market is assigning a relatively rich sales multiple compared with many companies in the same space.

Simply Wall St introduces a proprietary “Fair Ratio” to refine this picture. The Fair Ratio is an estimate of what P/S multiple might be reasonable for Liquidia after considering its earnings growth profile, industry, profit margins, market capitalization and company specific risks.

The Fair Ratio of 10.67x is meaningfully below the current 20.78x P/S. Based on this framework, and on a sales basis using these inputs, Liquidia is trading above what the model views as a fair level.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Liquidia Narrative

Earlier the article mentioned that there is an even better way to understand valuation, and Narratives are that tool. They let you attach a clear story about Liquidia to the numbers by linking assumptions for future revenue, earnings and margins to a financial forecast and then to a Fair Value that you can compare with the current price. All of this happens within Simply Wall St's Community page, where Narratives are refreshed as new news or earnings are released. For Liquidia, you might see one investor building a bullish story around earnings of $603.6 million and a Fair Value near US$67.00, while another uses a more cautious view with earnings of $23.4 million and a Fair Value around US$16.99. That spread helps you quickly see where your own view fits and what that might imply for whether the stock appears expensive or cheap to you today.

For Liquidia however we'll make it really easy for you with previews of two leading Liquidia Narratives:

First up is a version of the bullish case that lines up with the analyst consensus. It leans on strong growth assumptions for YUTREPIA and the broader pipeline, alongside improving margins and expanding manufacturing capacity.

Fair value in this bullish narrative: US$44.00

Implied discount to that fair value at US$37.34: about 15.2% undervalued

Assumed revenue growth: 118.06% per year

• YUTREPIA adoption, payer access and positive real world data are expected to support prescription volumes, revenue and margin improvement as awareness spreads.
• Planned manufacturing expansion in North Carolina and the L606 pipeline program are treated as key supports for scale, operating leverage and long run earnings power if demand is sustained.
• Analysts in this camp work toward a consensus price target of US$44.00 by tying higher revenue, stronger profit margins and a 16.6x P/E on 2029 earnings into their fair value view.

On the other side is a more cautious narrative that leans closer to the bearish analyst group and questions how much of the story is already priced in at current levels.

Fair value in this bearish narrative: US$16.99

Implied premium to that fair value at US$37.34: about 119.7% overvalued

Assumed revenue growth: 100.23% per year

• Expectations here factor in the risk that YUTREPIA adoption cools after the initial surge, in a niche pulmonary hypertension market that leans heavily on a single franchise.
• More cautious assumptions also reflect possible pressure from complex indication expansions, higher R&D and commercialization spend for L606, pricing pressure from large payers and legal or competitive risks around treprostinil.
• To arrive near US$16.99, this narrative pairs lower earnings and margin expectations with a high assumed 82.1x P/E on 2028 earnings, implying that current market expectations may already be demanding.

Both narratives are built from the same core facts but reach very different price anchors, which is why it helps to see them side by side and decide which set of assumptions sits closer to how you view Liquidia today.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Liquidia on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Liquidia? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.